Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs - ScienceDirect
Papel de la ribavirina en la terapia libre de interferón frente al virus de la hepatitisC | Gastroenterología y Hepatología
Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España
Velsof - Velpatasvir / sofosbuvir phác đồ có hiệu quả khỏi bệnh cao nhất trong điều trị viêm gan C mạn
Treatment algorithm for Hepatitis C virus patients under "National... | Download Scientific Diagram
Epclusa Retreatment of HCV Patients Previously Treated with SOF/VEL
SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen. - ppt download
SOF/VEL 400/100 mg qd N = 75 W24 SOF/VEL > 18 years Chronic HCV infection Genotype 1 to 6 Naïve or treatment-experienced No prior treatment with NS5A or. - ppt download
Sofosbuvir/ velpatasvir/ voxilaprevir (Vosevi)
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan | Scientific Reports
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treartment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection
Proportion achieving SVR12 among SOF/VEL patients overall, and by... | Download Scientific Diagram
IJERPH | Free Full-Text | Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study | HTML
Respuesta virológica sostenida en pacientes con hepatitis C crónica, tratados con antivirales de acción directa: un estudio retrospectivo en Costa Rica
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
Hepatitis C. No respondedores, tienen otra alternativa
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China | BMJ Open
Tractament antiviral de l'hepatitis C crònica a l'any 2019, 2020 i 2021
Sofosbuvir/Velpatasvir/Voxilaprevir: A Highly Effective Option for Retreatment of Hepatitis C in Difficult-to-treat Patients - Poonam Mathur, Shyamasundaran Kottilil, Eleanor Wilson, 2019
Informe de Posicionamiento Terapéutico de sofosbuvir/velpatasvir (Epclusa®) en hepatitis C
HIV Drug Therapy. Glasgow, UK. October 28-31, 2018
The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®) | springerprofessional.de
